Pulmo BioTech Inc. Announces Paper to be Presented at Symposium

    NEW YORK, May 4 /CNW/ -- Pulmo BioTech Inc. (OTC Bulletin Board:   PLMO;
Frankfort Borse: PLO) has announced that Dr. Jocelyn Dupuis, the Chief
Scientific Officer of its Pulmo Science Inc. subsidiary and the originator of
the PulmoBind concept is to present a paper at the 5th International Symposium
on Peptide Receptors and Kinin 2009 to be held in Quebec, Canada from June
26th to 29th.

    The paper, which is titled "Development of Radiolabeled Adrenomedullin
Analogs Designed for Molecular Imaging of the Pulmonary Circulation", will be
part of the session "From a Peptide to a Drug: Rational Drug Design".

    This multidisciplinary and highly prestigious symposium aims to bring
together outstanding scientists from around the world to discuss the most
recent developments and future trends in basic and clinical research on a
variety of peptides, neuropeptides and G-protein-coupled receptors (GPCR).

    "We are very pleased that Dr. Dupuis has been chosen to present a paper
on our Molecular Imaging technology at the Peptide Receptors International
Symposium. As a company, Pulmo BioTech Inc. believes strongly in the peer
review process and academic publishing, and we are delighted to have been
given the opportunity to bring to an open forum some of the technical details
of our development work." - Garry McCann, CEO Pulmo BioTech Inc.

    About Pulmo BioTech Inc.
    Pulmo BioTech Inc. specializes in the development and marketing of
medical technology and research. Our proven strengths combine extensive
commercial experience and academic credentials. The principal staff members
are acknowledged experts in their specialized fields, and work with a broad
range of investment institutions. Our mission is to utilize scientific
imagination and drive, together with managerial and financial acumen, to bring
innovative and profitable products to the marketplace to the benefit of all
stock holders.

    About PulmoScience Inc.
    PulmoScience Inc. was established in 2006, and is currently developing a
non-invasive Molecular Imaging technique for the diagnosis of Pulmonary
Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the
trade name PulmoBind.

    PulmoScience was conceived within the Montreal Heart Institute "MHI" (a
world renowned hospital and educational facility). Jointly owned by MHI
subsidiary Innovacor as the technical and operational partner, Dr. Jocelyn
Dupuis (the scientific director and originator of the PulmoBind Molecular
Imaging technology), and by Pulmo BioTech Inc. as the funding partner,
PulmoScience Inc. aims to develop this unique and exciting technology, to fund
necessary trials, and to bring the products to market.

    PulmoScience believes that the market for its product candidates is worth
in excess of $500 million per annum and that, provided Regulatory Approval is
achieved, the safety and efficacy of its products could allow it to dominate
that market.

    About PulmoBind
    PulmoBind uses an intravenously delivered radionuclide tagged molecule
which specifically bonds to the inner walls of the circulatory system in the
lungs, and by the use of an external Gamma Camera allows an image of the
integrity of the blood vessels throughout the lungs to be seen by a diagnostic
clinician. PulmoScience is currently undertaking Regulatory Approval for Phase
I Human Trials, and while subsequent results from additional tests might not
corroborate the current results, PulmoScience believes that PulmoBind has the
potential to dominate the market for the diagnosis of Pulmonary Embolism.  In
particular, this belief is driven by PulmoScience's expectations of the
improved safety and efficacy that PulmoBind will offer when compared to the
current incumbent nuclear medicine based technology for the diagnosis of
Pulmonary Embolism.  In addition, early indications are that PulmoBind could
be highly effective in the early stage diagnosis of Pulmonary Hypertension, a
condition for which there is no current front line diagnostic test. The
addressable market for the product candidates being developed by PulmoScience
is believed by the company to be worth in excess of $500 million per annum.

    Further Information
    For further information regarding Pulmo BioTech Inc. or PulmoScience,
please visit www.pulmobiotech.com.

    Forward-Looking Statements
    Forward-looking statements contained in this and other written and oral
reports are made based on known events and circumstances at the time of
release, and as such, are subject in the future to unforeseen uncertainties
and risks. All statements regarding future performance, earnings projections,
regulatory approval, events or developments are forward-looking statements. It
is possible that the future performance of the company may differ materially
from current expectations, depending on economic conditions and the
uncertainty of regulatory approval. A change in economic conditions may have a
particularly volatile effect on results. Among the other factors which may
affect future performance are: competitive market conditions and resulting
effects on sales and pricing; increases in raw-material costs that cannot be
recovered in product pricing; and global economic factors, including
difficulties entering new markets and general economic conditions such as
inflation, interest rates and credit availability. The company makes these
statements as of the date of this disclosure, and undertakes no obligation to
update them.

    ISIN: US7458451074
    CUSIP: 745845107


For further information:

For further information: Peter Hirshfield, +1-646-827-9362,
phirshfield@hirshfieldlaw.com  Web Site: http://www.pulmobiotech.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890